Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: A confirmatory study

BJU International

Volumn 107, Issue 11, 2011, Pages 1755-1761

  Steuber, Thomas ^a   Budäus, Lars ^a   Walz, Jochen ^b   Zorn, Kevin C ^c   Schlomm, Thorsten ^a   Chun, Felix ^a   Ahyai, Sascha ^a   Fisch, Margit ^a   Sauter, Guido ^a   Huland, Hartwig ^a   Graefen, Markus ^a   Haese, Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INSTITUT PAOLI CALMETTES   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cancer specific survival; lymph node metastasis; prostate cancer; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79956360761     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09730.x     Document Type: Article

References (26)

1. Gerber GS, Thisted RA, Chodak GW, et al,. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 385-90 (Pubitemid 27501033)
2. Da Pozzo LF, Cozzarini C, Briganti A, et al,. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009; 55: 261-70
3. Messing EM, Manola J, Yao J, et al,. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9 (Pubitemid 43779173)
4. Mattei A, Fuechsel FG, Bhatta Dhar N, et al,. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53: 118-25 (Pubitemid 350166722)
5. Bader P, Burkhard FC, Markwalder R, et al,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 849-54 (Pubitemid 36188105)
6. Mickisch GH, Garin A, van Poppel H, et al,. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-70 (Pubitemid 32913522)
7. Bristow RE, Tomacruz RS, Armstrong DK, et al,. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-59 (Pubitemid 34177431)
8. Kaplan RN, Rafii S, Lyden D,. Preparing the 'soil': the premetastatic niche. Cancer Res 2006; 66: 11089-93
9. Ghavamian R, Bergstralh EJ, Blute ML, et al,. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999; 161: 1223-7; discussion 1227-8
10. Boorjian SA, Thompson RH, Siddiqui S, et al,. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178 (3 Pt 1): 864-70; discussion 870-1
11. Schumacher MC, Burkhard FC, Thalmann GN, et al,. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54: 344-52
12. Grimm MO, Kamphausen S, Hugenschmidt H, et al,. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2002; 41: 628-34; discussion 634 (Pubitemid 35333920)
13. Schmeller N, Lubos W,. Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Br J Urol 1997; 79: 226-34
14. Cadeddu JA, Partin AW, Epstein JI, et al,. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997; 50: 251-5 (Pubitemid 27339942)
15. Engel J, Bastian PJ, Baur H, et al,. Survival benefit of radical prostatectomy in lymph node- positive patients with prostate cancer. Eur Urol 2010; 57: 754-61
16. Budaus L, Isbarn H, Schlomm T, et al,. Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 2009; 56: 317-24
17. Graefen M, Walz J, Huland H,. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006; 49: 38-48 (Pubitemid 41789952)
18. Cancer AJCO. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott, 1997
19. Gleason DF,. Histologic Grading and Clinical Staging of Prostate Carcinoma., Tannenbaum M, ed, Philadelphia: Lea and Febiger, 1977
20. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906 (Pubitemid 19011040)
21. Augustin H, Hammerer P, Graefen M, et al,. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol 2003; 43: 113-8 (Pubitemid 36221962)
22. Aus G, Hugosson J, Norlen L,. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995; 154 (2 Pt 1): 466-9
23. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
24. Albertsen PC, Fryback DG, Storer BE, et al,. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127-32 (Pubitemid 26185654)
25. Gallina A, Chun FK, Suardi N, et al,. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101: 1513-8 (Pubitemid 351704026)
26. Briganti A, Karnes JR, Da Pozzo LF, et al,. Two positive nodes represent a significant cut-off value for cancer-specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009; 55: 261-70